Long-term follow-up of early breast cancer study participants
Part of Cancer clinical trials.
This study follows people who previously took part in GEICAM early breast cancer trials to learn about long-term outcomes. It may help doctors understand what happens over time and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were included in past early breast cancer studies run with GEICAM (both before and after surgery).
- Your information from the earlier GEICAM studies is already in their records, but your long-term status wasn’t captured before.
- If you joined another clinical trial before or after, you may still qualify—your data can be collected too.
- You have not had your death or loss-of-contact status already recorded in the original study databases.
- You were not left out of the original study analyses due to not following study rules, or because you withdrew consent there.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well a previous early breast cancer treatment works over the long term and monitors safety. It may help you and future patients by providing long-term results from the original trial.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
This study collects medical information from people with gastrointestinal (GI) cancer, both those treated in the past and those currently receiving care. The goal is to learn more about the disease and improve future treatments.
This follow-up study is for people who took part in earlier breast cancer gene tests (TAILORx or RxPONDER). It collects health information and tumor tissue over time to learn more about how breast cancer behaves after treatment.
This study invites women who finished treatment for non-metastatic invasive breast cancer to share health information and biological samples for future research. It may help scientists understand survivorship and improve care after treatment.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
Hear when a new Invasive Breast Cancer Early Stages trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.